tbuckley/cabot-search huggingface dataset:
The efficacy and safety of modified FOLFIRINOX as first‐line chemotherapy for Chinese patients with metastatic pancreatic cancer
Authors: Zhi‐Qiang Wang, Fei Zhang, Ting Deng, Le Zhang, Fen Feng, Feng‐Hua Wang, Wei Wang, De‐Shen Wang, Hui‐Yan Luo, Rui‐Hua Xu, Yi Ba, Yu‐Hong Li
Journal: Cancer Communications (2019)

Abstract Background Oxaliplatin, irinotecan, 5‐fluorouracil, and l ‐leucovorin (FOLFIRINOX) has become one of the first‐line treatment options for advanced pancreatic cancer (PC). However, the relatively high rate of grade 3 or 4 adverse events associated with the standard dosage of FOLFIRINOX limits its widespread use in clinical practice. In this study, we were to evaluate the efficacy and safety of a modified FOLFIRINOX regimen as a first‐line chemotherapy for Chinese patients with metastatic PC. Methods Patients with histologically confirmed primary metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2 were recruited to receive the modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m 2 ; irinotecan, 150 mg/m 2 ; l ‐leucovorin, 200 mg/m 2 ; and 5‐fluorouracil, 2400 mg/m 2 , repeated every 2 weeks). The treatment was continued for 12 cycles unless the patient had progressive disease (PD), stable disease (SD) with symptom deterioration, unacceptable adverse events, or requested to terminate the treatment prematurely. The primary endpoint was objective response rate (ORR). Results Sixty‐five patients were enrolled from July 2012 to April 2017 in three institutions, and they all received at least one cycle of chemotherapy, with a median of 8 cycles (range 1–12 cycles). No complete response was observed. Twenty‐one (32.3%) patients had partial responses, and 27 (41.5%) had SD. The ORR and disease control rate of the study cohort was 32.3% and 73.8%. The estimated median overall survival and progression‐free survival were 11.60 (95% confidence interval [CI] 8.76–14.44) and 5.77 (95% CI 5.00–6.54) months. Major grade 3 or 4 adverse events included neutropenia (12.3%) and diarrhea (6.2%). No treatment‐related death was observed. Conclusions Modified FOLFIRINOX was well‐tolerated and might be a promising option as first‐line therapy for Chinese patients with metastatic PC. Trial registration ClinicalTrials.gov , NCT02028806. Registered 7 January 2014, https://clinicaltrials.gov/ct2/show/NCT02028806
Taxonomizing Views of Clinical Ethics Expertise
Authors: Abram Brummett, Erica K. Salter
Journal: The American Journal of Bioethics (2019)

Our aim in this article is to bring some clarity to the clinical ethics expertise debate by critiquing and replacing the taxonomy offered by the Core Competencies report. The orienting question for our taxonomy is: Can clinical ethicists offer justified, normative recommendations for active patient cases? Views that answer "no" are characterized as a "negative" view of clinical ethics expertise and are further differentiated based on (a) why they think ethicists cannot give justified normative recommendations and (b) what they think ethicists can offer, if they cannot offer recommendations. Views that answer "yes" to the orienting question are characterized as a "positive" view of clinical ethics expertise. Positive views are distinguished according to four additional questions. First (P1), how are those recommendations generated? Second (P2), what is the nature of the recommendations? Third (P3), we ask, how are the recommendations justified? And finally (P4), how are the recommendations communicated?
Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors
Authors: S. Hameed, A. Jamshed, R. Hussain, M. Ali, H. Iqbal, U. Majeed, M. A. Shah
Journal: Journal of Clinical Oncology (2009)

6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial. The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients. Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT). Methods: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution. There were 15 males and 6 females (M 71%:F 29%) with a median age of 49 years (range 19 - 70 years). Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients. Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients. Induction chemotherapy consisted of cisplatin 75 mg / metre 2 day 1 and gemcitabine 1 gm / metre 2 day 1 and 8 every three weeks. Eighty-five percent (18/21) received 2 cycles of neoadjuvant chemotherapy (range 1–4 cycles) prior to radiotherapy. Radiotherapy dose was 54 Gy - 70 Gy (median radiation dose 66 Gy). Fifty-seven percent (12/21) received concomitant cisplatin with radiotherapy. Results: Response to neoadjuvant chemotherapy; complete in 19% (4), partial in 67% (14), no response/progression 14% (3). Following RT/CRT 86% (18/21) had complete regression of disease. Thirty-three percent (7/21) have failed treatment (local 3, regional 2, and distant metastasis in 2 patients). Among treatment failures 2 patients were successfully salvaged; surgery for local recurrence in one patient and in the other case radiation was given for regional recurrence. Disease free and overall survival at 40 months was 52% and 63%, respectively. Conclusions: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors. In combination with RT/CRT survival rates are encouraging and the approach merits further investigations in clinical trials. No significant financial relationships to disclose.
Abstract 12167: Systematic Assessment of the Impact of Contrast Enhancement Upon Measurements of Cardiac Size and Function by Echocardiography
Authors: Sachiyo Igata, Monet Strachan, Megan Kraushaar, Janet Ma, Marin Nishimura, Iwona Swiatkiewicz, Ajit Raisinghani, Anthony N DeMaria
Journal: Circulation (2018)

Background: Contrast echocardiography is a powerful tool for identifying the endocardial border. However, the precise relationship of measurements obtained from contrast echo to the reference value...
EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients
Authors: Y. Huang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
P1.09-02 Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer in Brazil (GBOT 0118/LACOG 0418)
Authors: E. Mascarenhas, A. Gelatti, V. De Lima, L.H. Araújo, C. Baldotto, C. Mathias, M. Zukin, G. Werutsky, P.R. Nunes Filgo, R. Gomes, G. Castro
Journal: Journal of Thoracic Oncology (2019)
P2.01-56 Copy Number Gains (CNGs) of Clinically Relevant Genes in Advanced NSCLC Patients
Authors: M. Garzón, N. Jordana, B. García, R. Román, J. Bertrán-Alamillo, S. Rodriguez, E. Aldeguer, S. Garcia Román, S. Viteri, A. Aguilar Hernandez, M. Gonzalez-Cao, M. Fernández-Bruno, N. Karachaliou, A. Martinez-Bueno, I. Moya, M.A. Molina-Vila, R. Rosell, C. Mayo De Las Casas
Journal: Journal of Thoracic Oncology (2019)
Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis
Authors: Jian Mao, Binghui Qiu, Fen Mei, Fan Liu, Zhanpeng Feng, Jun Fan, Jing Nie, Lijun Huang, Xixian Liao, Zhenhao Wang, Jiahui Zeng, Zelin Weng, Nailiang Zang, Songtao Qi, Yun Bao
Journal: Metabolism (2019)
P2.14-13 Elevated Expression of Eukaryotic Translation Initiation Factor 3 Subunit C Contributes to EGFR-TKI Resistance in Lung Adenocarcinoma
Authors: T. Shintani, K. Higashisaka, M. Maeda, K. Kawasaki, S. Maeda, T. Yamamoto, E. Morii, A. Kumanogoh, Y. Tsutsumi, I. Nagatomo, Y. Miwa, Y. Fujio
Journal: Journal of Thoracic Oncology (2019)
P1.04-24 Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Authors: J. Koh, Y. Kim, K.Y. Lee, M.S. Kim, B.M. Ku, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2019)
Dual targeting of EGFR and HER-2 in breast cancer cell lines
Authors: N. O’Donovan, J. P. Crown, M. Clynes
Journal: Journal of Clinical Oncology (2006)

13132 Background: ErbB2 is overexpressed in approximately 25–30% of breast cancers. Recent studies have shown that overexpression of ErbB2 is also frequently associated with expression of ErbB1 and that ErbB1 expression influences response to ErbB2 inhibition. The aim of this study was to investigate the effects of dual targeting of ErbB1 and ErbB2 in ErbB2 overexpressing breast cancer cell lines. Methods: Combinations of Trastuzumab (Herceptin), Gefitinib (Iressa) and Lapatinib (GW572016) were tested in two ErbB2 and ErbB1 positive breast cancer cell lines, SKBR3 and BT474. Proliferation assays were performed using the acid phosphatase assay and apoptosis was measured using the Cell Death Detection ELISA (Roche). The average combinations index (CI) values at ED 25 , ED 50 and ED 75 were determined using CalcuSyn. Results: With regard to inhibition of proliferation, dual targeting with Trastuzumab and Gefitinib is additive (CI=0.8) in SKBR3 cells and synergistic (CI=0.6) in BT474 cells. Combined treatment with Trastuzumab and Lapatinib is synergistic (CI=0.5) in SKBR3 cells and additive (CI=1.0) in BT474 cells. Dual targeting with Gefinitib and Lapatinib is antagonistic in both cell lines. Trastuzumab (10 nM) alone and Gefitinib (5 μM) alone did not induce significant apoptosis in SKBR3 cells whereas Lapatinib (0.75 μM) alone induced apoptosis and in combination with Trastuzumab enhanced apoptosis induction. Combined treatment with Trastuzumab (10 nM) and Gefitinib (5 μM) induced apoptosis comparable to Lapatinib alone (0.75 μM). Conclusions: Our results suggest that dual targeting of ErbB1 and ErbB2 with combinations of the monoclonal antibody, Trastuzumab and tyrosine kinase inhibitors may improve response to treatment in a sub-group of patients with ErbB2 overexpressing tumours that also express ErbB1. Interestingly, the apoptosis assays suggest that inhibition of both ErbB1 and ErbB2 is required to efficiently induce apoptosis in cells which express both receptors. [Table: see text]
EP1.12-23 Surgery Is Associated with Favorable Outcome in Patients with Early Stage SCLC – Retrospective Institutional Experience
Authors: T. Klikovits, K. Sinn, E. Gschwandtner, N. Kasbauer, S. Taghavi, W. Klepetko, M.A. Hoda
Journal: Journal of Thoracic Oncology (2019)
P2.01-77 PET CT Radiogenomic Depiction with EGFR and ALK Molecular Alterations in Lung Cancer Among Indian Population
Authors: A. Jajodia, R. Tripathi, A. Chaturvedi, V.P.B. Koyyala, S. Pasricha, S. Goyal, U. Batra, A. Mehta, H. Prosch
Journal: Journal of Thoracic Oncology (2019)
MA13.03 Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis
Authors: N. Vilariño, J.A. Marín, M. Simó, R. Velasco, M. Alemany, M. Jove, J.C. Ruffinelli, I. Brao, M. Arellano, R. Palmero Sánchez, J. Bruna, E. Nadal
Journal: Journal of Thoracic Oncology (2019)
P2.01-76 Bone Metastasis and Pleural Dissemination as a Potential Marker for Predicting of T790M Mutation in Advanced Non-Small Cell Lung Cancer Patients
Authors: Y. Mizushina, F. Ohyanagi, M. Nomura, F. Kudo, J. Shiihara, H. Ohta, S. Koyama
Journal: Journal of Thoracic Oncology (2019)
Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)
Authors: Mohit Narang, Rafat Abonour, Brian G. M. Durie, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Sundar Jagannath, Howard R. Terebelo, Lynne Wagner, Shankar Srinivasan, E. Dawn Flick, Faiza Zafar, Amani Kitali, Amit Agarwal, Robert M Rifkin
Journal: Blood (2017)
The 3ʹ-untranslated region contributes to the pregnane X receptor (PXR) expression down-regulation by PXR ligands and up-regulation by glucocorticoids
Authors: Tomas Smutny, Jan Dusek, Lucie Hyrsova, Jana Nekvindova, Alzbeta Horvatova, Stanislav Micuda, Sabine Gerbal-Chaloin, Petr Pavek
Journal: Acta Pharmaceutica Sinica B (2019)

Pregnane X receptor (PXR) is the major regulator of xenobiotic metabolism. PXR itself is controlled by various signaling molecules including glucocorticoids. Moreover, negative feed-back regulation has been proposed at the transcriptional level. We examined the involvement of the 3'-untranslated region (3'-UTR) of NR1I2 mRNA and microRNAs in PXR- and glucocorticoid receptor (GR)-mediated regulation of NR1I2 gene expression. PXR ligands were found to significantly downregulate NR1I2 mRNA expression in a set of 14 human hepatocyte cultures. Similarly, PXR was downregulated by PCN in the C57/BL6 mice liver. In mechanistic studies with the full-length 3'-UTR cloned into luciferase reporter or expression vectors, we showed that the 3'-UTR reduces PXR expression. From the miRNAs tested, miR-18a-5p inhibited both NR1I2 expression and CYP3A4 gene induction. Importantly, we observed significant upregulation of miR-18a-5p expression 6 h after treatment with the PXR ligand rifampicin, which indicates a putative mechanism underlying NR1I2 negative feed-back regulation in hepatic cells. Additionally, glucocorticoids upregulated NR1I2 expression not only through the promoter region but also via 3'-UTR regulation, which likely involves downregulation of miR-18a-5p. We conclude that miR-18a-5p is involved in the down-regulation of NR1I2 expression by its ligands and in the upregulation of NR1I2 mRNA expression by glucocorticoids in hepatic cells.
The Impacts of Transcriptional Regulatory Mechanism and Protein Interaction Relationship between RUNX1 and KLF4 on the Biological Functions of t (8;21) Leukemia Cells
Authors: Shuang Liu, Wenting Lu, Shouyun Li, Saisai Li, Ying Wang, Jia Liu, Zheng Tian, Haiyan Xing, Kejing Tang, Yingxi Xu, Qing Rao, Min Wang, Jianxiang Wang
Journal: Blood (2017)
P1.04-26 EMT-Associated Response and Resistance to MEK Inhibitor and Immune Checkpoint Blockade Combinations in KRAS-Mutant NSCLC
Authors: P. Gaudreau, D. Peng, B. Rodriguez, J. Fradette, L. Gibson, C. Della Corte, T. Sen, S. Kundu, L. Chen, J. Wargo, D. Gibbons
Journal: Journal of Thoracic Oncology (2019)
Examining the Shape of the Association between Low Levels of Fine Particulate Matter and Mortality across Three Cycles of the Canadian Census Health and Environment Cohort
Authors: Amanda J. Pappin, Tanya Christidis, Lauren L. Pinault, Dan L. Crouse, Jeffrey R. Brook, Anders Erickson, Perry Hystad, Chi Li, Randall V. Martin, Jun Meng, Scott Weichenthal, Aaron van Donkelaar, Michael Tjepkema, Michael Brauer, Richard T. Burnett
Journal: Environmental Health Perspectives (2019)

Ambient fine particulate air pollution with aerodynamic diameter ≤2.5 μm (PM2.5) is an important contributor to the global burden of disease. Information on the shape of the concentration-response relationship at low concentrations is critical for estimating this burden, setting air quality standards, and in benefits assessments.We examined the concentration-response relationship between PM2.5 and nonaccidental mortality in three Canadian Census Health and Environment Cohorts (CanCHECs) based on the 1991, 1996, and 2001 census cycles linked to mobility and mortality data.Census respondents were linked with death records through 2016, resulting in 8.5 million adults, 150 million years of follow-up, and 1.5 million deaths. Using annual mailing address, we assigned time-varying contextual variables and 3-y moving-average ambient PM2.5 at a 1×1 km spatial resolution from 1988 to 2015. We ran Cox proportional hazards models for PM2.5 adjusted for eight subject-level indicators of socioeconomic status, seven contextual covariates, ozone, nitrogen dioxide, and combined oxidative potential. We used three statistical methods to examine the shape of the concentration-response relationship between PM2.5 and nonaccidental mortality.The mean 3-y annual average estimate of PM2.5 exposure ranged from 6.7 to 8.0 μg/m3 over the three cohorts. We estimated a hazard ratio (HR) of 1.053 [95% confidence interval (CI): 1.041, 1.065] per 10-μg/m3 change in PM2.5 after pooling the three cohort-specific hazard ratios, with some variation between cohorts (1.041 for the 1991 and 1996 cohorts and 1.084 for the 2001 cohort). We observed a supralinear association in all three cohorts. The lower bound of the 95% CIs exceeded unity for all concentrations in the 1991 cohort, for concentrations above 2 μg/m3 in the 1996 cohort, and above 5 μg/m3 in the 2001 cohort.In a very large population-based cohort with up to 25 y of follow-up, PM2.5 was associated with nonaccidental mortality at concentrations as low as 5 μg/m3. https://doi.org/10.1289/EHP5204.
A two-step precise targeting nanoplatform for tumor therapy via the alkyl radicals activated by the microenvironment of organelles
Authors: Lei Wang, Xiuxiu Niu, Qingling Song, Jiajia Jia, Yongwei Hao, Cuixia Zheng, Kaili Ding, Huifang Xiao, Xinxin Liu, Zhenzhong Zhang, Yun Zhang
Journal: Journal of Controlled Release (2019)
MA23.01 Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study
Authors: W. Lam, A. Nowak, F. Chen, S. Muruganandan, S. Arunachalam, M. Chin, M. Millward, C. Read, K. Murray, J. Creaney, Y.C.G. Lee
Journal: Journal of Thoracic Oncology (2019)
P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
Authors: O. Arrieta, A. Ruiz-Patiño, A.F. Cardona, C. Martín, L. Raez, L. Zatarain Barron, F. Barrón, L. Ricaurte, M.A. Bravo-Garzón, L. Mas, L. Corrales-Rodriguez, L. Rojas, L. Lupinacci, F. Perazzo, C. Bas, O. Carranza, C. Pupareli, M. Rizzo, R. Ruiz Mendoza, C.D. Rolfo, P. Archila, J. Rodríguez, C. Sotelo, C. Vargas, H. Carranza, J. Otero, L.E. Pino, C. Ortíz, P. Laguado, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
EP1.09-17 Spanish Lung Cancer Biomarker Testing Registry (Lungpath): Descriptive Analysis Focus in ALK Traslocation Results
Authors: J. Martin Lopez, L. Aduz Alexandre, S. Gatius Caldero, A. Navarro Gonzales, P. Saiz Lopez, C. Gomez Bellvert, C. Camacho García, L. Melgar, E. Costa Navarro, I. Abdulkader Nallib, C.A. Vasquez Dongo, M. Saiz Camin, A. Yagüe Hernando, L. Atienza Cuevas, L. Pijuan, T. Hernández Iglesias, A. Martinez Pozo, C. Salas Anton
Journal: Journal of Thoracic Oncology (2019)
EP1.11-17 The Impact of Occupational Exposure on Detection of Extra-Nodular and Extrapulmonary Lesions in LDCT from a Pilot Silesian Study
Authors: S. Szablowska-Siwik, E. Wachula, W. Bulska-Bedkowska, D. Czyzewski, M. Adamek
Journal: Journal of Thoracic Oncology (2019)
HPV infection concurrence in the cervix and oral mucosa of Tobagonian women
Authors: Camille C. Ragin, Victor W. Wheeler, Jacqui B. Wilson, Clareann H. Bunker, Alan L. Patrick, Susanne M. Gollin
Journal: Cancer Research (2006)

475  Human papillomavirus (HPV) is a sexually transmitted virus attributed to more than 95% of cervical cancer and is associated with about 20% of head and neck tumors. According to the International Agency for Research on Cancer (IARC), the incidence and mortality rates for cervical cancer are ranked 3rd among women in Trinidad and Tobago. Although the prevalence of cervical cancer in Tobago is currently unknown, a high mortality rate due to cervical cancer was determined by a Tobago Health Needs Assessment in 1997. In the context of a cervical cancer screening study, we determined the prevalence of cervical and oral HPV infection in 212 Tobagonian women (ages 17-65 years), and identified factors associated with concurrent infections at both mucosal sites. Subjects were recruited from July to September, 2005. Pap smears, interviewer-administered questionnaires, a cervical brushing, mouthwash gargle and a self-administered questionnaire on sexual practices were collected for all participants. DNA was tested for HPV by nested PGMY09/11 and GP5+/6+ PCR and positive samples were genotyped using a HPV linear array protocol and pyrosequencing. Cervical HPV was detected in 74/212 (35%) women, while 14/212 (6.6%) had oral HPV, of which 7/14 (50%) had concurrent infections in the oral mucosa and cervix. Among women with oral HPV, 3/14 (21%) carried high-risk HPV types, two had HPV16 (one co-infected with HPV66) and one with HPV31. Oral HPV infection was more likely to occur in women whose age at 1st coitus was >18 years (OR = 2.6, 95% CI 0.8-8.5 p=0.1) and in women with abnormal cervical cytology (OR = 8.7, 95% CI = 1.4-52.7 p 0.1). In this study population, the prevalence of HPV infection differs between the oral mucosa and cervix. Oral HPV infection is associated with abnormal cervical cytology, and a high proportion of women with oral HPV had concurrent infections. These findings suggest that the association between oral and cervical high-risk infection warrants further study, specifically the distribution of HPV types in the cervix and oral cavity over time.
P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
Authors: A. Romero, E. Jantus, M.A. Molina-Vila, A. Insa, P. Cruz, A. Collazo, J. Perez Altozano, O. Juan, P. Diz, M. Cobo, B. Hernandez, S. Vazquez, G. Benitez, M. Guirado, M. Majem, R. Bernabe, A.L. Ortega, A. Blasco, J. Bosch-Barrera, J.M. Jurado, J. Garcia, S. Viteri, C. Garcia Giron, B. Massuti, A. Lopez Martin, B. Garcia-Pelaez, F. Aparisi, E. Sánchez Romero, A. Rodríguez Festa, S. Calabuig-Fariñas, R. Rosell, C. Camps, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
EP1.01-39 A Randomised Phase II Trial of Vitamin C Synergy with Hyperthermia in Patients with Advanced Non-Small-Cell Lung Cancer
Authors: J. Ou, X. Zhu, P. Chen, Y. Du, Y. Lu, X. Peng, S. Bao, J. Wang, X. Zhang, T. Zhang, C.L.k. Pang
Journal: Journal of Thoracic Oncology (2019)
MA04.07 Inhibition of CXCR2+ Neutrophil Migration as a Targeted Therapy in KRAS-Driven Lung Adenocarcinoma
Authors: M. De Meo, R. Rayes, S. Milette, M. Vagai, M. Usatii, A. Chandrasekaran, B. Giannias, F. Bourdeau, C. Moraes, S. Huang, D. Quail, L. Walsh, V. Sangwan, N. Bertos, S. Camilleri-Broet, P. Broet, P. Fiset, J. Cools-Lartigue, L. Ferri, J. Spicer
Journal: Journal of Thoracic Oncology (2019)
OA01.05 Cryobiopsy Compared with Forceps Biopsy in Pathological Diagnosis and Biomarker Research in Lung Cancer: A Prospective, Single-Arm Study
Authors: T. Naito, H. Udagawa, K. Kirita, T. Ikeda, Y. Zenke, S. Matsumoto, K. Yoh, S. Niho, G. Ishii, K. Goto
Journal: Journal of Thoracic Oncology (2019)
EP1.06-07 In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities
Authors: M. Giladi, S. Davidi, M. Munster, R. Schneiderman, N. Kaynan, T. Voloshin, Y. Porat, S. Cahal, E. Kirson, U. Weinberg, Y. Palti
Journal: Journal of Thoracic Oncology (2019)
P2.12-14 A Pilot Study of Serial Plasma Metabolomics in Small Cell Lung Cancer Patients
Authors: S. Lee, K. Pathak, M. Mcgilvrey, K. Mansfield, D. Cridebring, D. Roe, T. Whitsett, P. Pirrotte, J. Sun, J.S. Ahn, M. Ahn, K. Park
Journal: Journal of Thoracic Oncology (2019)